We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$589M
AUM Growth
+$77.1M
Cap. Flow
+$17.1M
Cap. Flow %
2.91%
Top 10 Hldgs %
37.04%
Holding
153
New
41
Increased
30
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.2M
2
GILD icon
Gilead Sciences
GILD
+$15.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$11.6M
4
TSRO
TESARO, Inc.
TSRO
+$7.96M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$25.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.09M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.32M
4
NVS icon
Novartis
NVS
+$4.35M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 66.11%
2 Technology 6.31%
3 Industrials 2.63%
4 Communication Services 2.28%
5 Financials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
76
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.25M 0.38%
+40,000
New +$1.6M
NDRM
77
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.23M 0.38%
+74,500
New +$1.93M
PRTA icon
78
Prothena Corp
PRTA
$425M
$2.17M 0.37%
+40,000
New +$2.13M
ALBO
79
DELISTED
Albireo Pharma Inc
ALBO
$2.13M 0.36%
+103,526
New +$2.12M
DOVA
80
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$2.12M 0.36%
+95,000
New +$2M
ORLY icon
81
CALL
O'Reilly Automotive
ORLY
$72.9B
$2.04M 0.35%
+1,500
New +$24.5K
TMO icon
82
Thermo Fisher Scientific
TMO
$213B
$2.04M 0.35%
11,688
+4,775
+69% +$802K
OBSV
83
DELISTED
ObsEva SA Ordinary Shares
OBSV
$1.98M 0.34%
231,497
+20,411
+10% +$152K
SGEN
84
DELISTED
Seagen Inc. Common Stock
SGEN
$1.86M 0.32%
36,000
– –
MRNS
85
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.82M 0.31%
332,855
– –
TJX icon
86
TJX Companies
TJX
$174B
$1.78M 0.3%
49,400
+4,000
+9% +$151K
ARDX icon
87
Ardelyx
ARDX
$1.22B
$1.76M 0.3%
345,000
– –
PRQR icon
88
ProQR Therapeutics
PRQR
$243M
$1.72M 0.29%
330,000
– –
SPNS
89
DELISTED
Sapiens International
SPNS
$1.65M 0.28%
147,306
– –
AKAO
90
DELISTED
Achaogen Inc
AKAO
$1.63M 0.28%
75,000
-125,000
-63% -$2.85M
TSEM icon
91
Tower Semiconductor
TSEM
$24.8B
$1.6M 0.27%
67,155
– –
SMMT icon
92
Summit Therapeutics
SMMT
$10.4B
$1.56M 0.27%
142,018
-5,432
-4% -$61.2K
FLEX icon
93
Flex
FLEX
$41.7B
$1.54M 0.26%
+125,402
New +$1.55M
PDSB icon
94
PDS Biotechnology
PDSB
$38.4M
$1.54M 0.26%
7,500
– –
WAB icon
95
Wabtec
WAB
$49.1B
$1.52M 0.26%
+16,600
New +$1.38M
VTVT icon
96
vTv Therapeutics
VTVT
$127M
$1.49M 0.25%
7,500
– –
MGNX icon
97
MacroGenics
MGNX
$235M
$1.42M 0.24%
81,200
– –
OEF icon
98
CALL
iShares S&P 100 ETF
OEF
$20.1B
$1.42M 0.24%
100
– –
MA icon
99
Mastercard
MA
$502B
$1.4M 0.24%
11,525
– –
RNTX
100
Rein Therapeutics
RNTX
$63.1M
$1.39M 0.24%
+6,250
New +$1.37M
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sphera Funds Management held 153 positions worth $589M, up 15% from $512M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sphera Funds Management's Q2 2017 filing shows 41 new, 30 increased, 20 reduced and 25 closed positions. Its largest new stake was GSK: 360,000 shares worth $19.4M. The largest sale was Shire pic, an estimated $25.5M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q2 2017 buy was GSK: 360,000 shares worth $19.4M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $5.33M increase.
  • Sphera Funds Management's biggest Q2 2017 reduction was Shire pic, cutting an estimated $25.5M.
  • Sphera Funds Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $7.09M.
  • Sphera Funds Management's ten largest holdings make up 37% of its $589M portfolio in Q2 2017.
  • Sphera Funds Management opened 41 new positions and closed 25 in Q2 2017.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $589M.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.